TN-16

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: TN-16
• 英文别名: 5-Benzyl-3-(1'-anilinoethyliden)pyrrolidin-2,4-dion；(3Z)-3-(1-anilinoethylidene)-5-benzylpyrrolidine-2,4-dione
• 化学式: C₁₉H₁₈N₂O₂
• 分子量: 306.364
• InChiKey: KWSXUGYAGMSUTN-LGMDPLHJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Methods and compositions for stimulating bone growth using inhibitors of microtubule assembly
  申请人：——

  公开号：US20030181374A1

  公开（公告）日：2003-09-25

  The invention relates to compositions and methods for use in treating skeletal system disorders in a vertebrate at risk for bone loss, and in treating conditions that are characterized by the need for bone growth, in treating fractures, and in treating cartilage disorders. More specifically, the invention concerns the use of inhibitors of microtubule assembly for enhancing bone growth.

  本发明涉及用于治疗有骨质流失风险的脊椎动物骨骼系统疾病的组合物和方法，以及用于治疗以骨生长需求为特征的疾病、治疗骨折和治疗软骨疾病的组合物和方法。更具体地说，本发明涉及使用微管组装抑制剂促进骨骼生长。
• CELL-CYCLE-DEPENDENT REGULATION OF PHOSPHORYLATION OF HUMAN RETINOBLASTOMA GENE PRODUCT
  申请人：RESEARCH DEVELOPMENT FOUNDATION

  公开号：EP0504289A1

  公开（公告）日：1992-09-23
• JPH08308571A
  申请人：——

  公开号：JPH08308571A

  公开（公告）日：1996-11-26
• Bone growth stimulation with NO/statin and other NO modulating combinations
  申请人：OSTEOSCREEN

  公开号：US20040254238A1

  公开（公告）日：2004-12-16

  Methods and compositions provided herein relate to the promotion of bone formation and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation. Disclosed is a method of enhancing bone formation by administering at least two components selected from at least one statin-like compound, at least one nitric oxide generating system, and at least one phosphodiesterase inhibitor. Also disclosed is a pharmaceutical composition comprising said at least two components.
• DRUG COMBINATIONS TO TREAT HYPERPROLIFERATIVE DISORDERS
  申请人：Maurer Barry James

  公开号：US20100035911A1

  公开（公告）日：2010-02-11

  A method of treating a hyperproliferative disorder, including a cancer, in a subject in need of such treatment, comprising administering to said subject a pharmaceutical combination containing a treatment effective amount of: (a) a vitamin A derivative (i.e., a retinoid), or a pharmaceutically acceptable salt thereof, and an inhibitor of microtubule structure or function; or (b) a combination containing fenretinide (i.e., N-(4-hydrophenyl) retinamide, 4-HPR) and ABT-751 (i.e., N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide). Vitamin A derivatives that may be useful for this invention according to (a) include, but are not limited to, all-trans-retinoic acid, 13-cis-retinoic acid, and fenretinide. Microtubule inhibitors that may be useful for this invention according to (a) include, but are not limited to, inhibitors of the Vinca binding domain (e.g., vincristine, vinblastine, vinorelbine, and cryptophycin 52), inhibitors of the Taxane domain (e.g., paclitaxel, docetaxel, and epothilones), and inhibitors of the colchicine site (e.g., colchicine, ABT-751, CI-980, and combretastatin). A preferred retinoid according to (a) is fenretinide. A preferred microtubule inhibitor according to (b) is ABT-751.

表征谱图